The University of Tokyo

Perseus Proteomics Inc.

Nissan Chemical Industries Limited

Kowa Company Limited

Chugai Seiyaku Kabushiki Kaisha

Toudai Tlo, Ltd.

Other

Aichi Medical University

Institute of Immunology Co., Ltd.

Takao Hamakubo

Kenji Inoue

Tatsuhiko Kodama

Hiroko Iwanari

Yasuomi Urano

Akira Sugiyama

Hiroyuki Aburatani

Masao Ohkuchi

Isao Kohno

Yoshikazu Shibasaki

Ryoichi Saitoh

Taisuke Tomita

Takeshi Iwatsubo

Ikuo Hayashi

Yasuhiro Mochizuki

Takahide Kohro

Yukio Ito

Takeshi Ito

Yoshinori Murakami

Osamu Arai

Ta-Yuan Chang

Hirofumi Doi

Yoshiki Yamada

Hiroshi Itoh

Iwao Ohizumi

Mineko Yamaguchi

Hirotaka Itoh

Toshimitsu Momose

Kouhei Tsumoto

Yoshitaka Kumakura

Masahito Tsurusawa

Toshiko Sakihama

Kazuyuki Masuda

Yoshiki Kawabe

Shunsuke Niwa

Yoshiko Nakada

Toshiyuki Kitoh

Koji Maemura

Kenji Daigo

Naotaka Yamaguchi

Motoaki Mizuuchi

Hiroya Fujii

Yoshikazu Sibasaki

Koji The University Of Tokyo Maemura

Iwao Chugai Seiyaku Kabushiki Kaisha Ohizumi

Ryoichi Chugai Seiyaku Kabushiki Kaisha Saitoh

The present invention provides an antibody recognizing a v9 fragment of the cell adhesion molecule CADM1.

CADM1 V9-recognizing antibody

It is an object of the present invention to provide a monoclonal antibody, which is suitable for the quantitative analysis of asparagine synthetase in a cell. The present invention provides a monoclonal antibody which specifically recognizes asparagine synthetase that is present in a cell.

Monoclonal antibody specifically recognizing asparagine synthetase

[Theme] To provide a monoclonal antibody against human GPR87. Also, to provide a novel means for diagnosing or treating a malignant tumor. [Solution means] Monoclonal antibodies against human GPR87 are provided. The antibodies can recognize human GPR87, which is expressed on a cell membrane while retaining a three-dimensional structure, and can recognize GPR87, which is expressed in a cell endogenously with an epitope being present in an extracellular domain of full-length human GPR87. The antibodies are thus useful in biochemical analysis, etc., of GPR87, useful in immunohistological diagnosis, etc., of squamous cell carcinoma, and also potentially useful in PET diagnosis, antibodies for treatment, etc., of squamous cell carcinoma.

Monoclonal antibody, and use thereof

It is intended to provide an inhibitor for the formation of a &#x3b3;-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of &#x3b3;-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of &#x3b3;-secretase. Moreover, it is intended to provide a method of screening an effect of a test substance on &#x3b3;-secretase which comprises measuring the distribution of constituents (niscastrin, APH-1, Pen-2 and so on) required by &#x3b3;-secretase for the formation of its active complex in cells.

Inhibitor for the formation of gamma-secretase complex

It is an object of the present invention to provide a mutant streptavidin wherein the immunogenicity (antigenicity) in mammals of a streptavidin is reduced. The present invention provides a mutant streptavidin, which comprises an amino acid sequence in which (a) the arginine residue at position 72 is substituted with another amino acid residue, and (b) any one or more of the tyrosine residue at position 10, the tyrosine residue at position 71, the glutamic acid residue at position 89, the arginine residue at position 91, and the glutamic acid residue at position 104 are substituted with other amino acid residues, with respect to the amino acid sequence of a core streptavidin as shown in SEQ ID NO: 2, and which has decreased immunogenicity as compared with that of a wild-type streptavidin.

Streptavidin having low immunogenicity and use thereof

To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.

Therapeutic agents for alzheimer's disease and cancer

A nuclear transfer promoter for Rac protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Rac protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Rac protein to transfer into nucleus.

Nuclear transfer promoter for Rac protein and method of screening the same

A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus.

Method of screening pharmaceutical compositions that promote nuclear transfer of Cdc42 protein

To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.

Method of measuring PTX3 with high sensitivity

It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.

Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody

The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer.

Antibodies that inhibit transport activity of peptide transporters

The present inventors extensively studied and found that an antibody binding to PepT has cytotoxic activity and inhibits cell growth. These results suggest that an antibody binding to PepT, particularly an antibody having a cytotoxic activity, can be used as a cell growth inhibitor, for example, in treating and preventing cancer.

Cell growth inhibitor containing anti-PepT antibody

The object of the present invention is to develop a technique for expressing a functional membrane-bound protein by using baculovirus and insect cell expression system. The present invention provides a method for expressing a functional membrane-bound receptor protein which comprises steps of culturing a host infected with at least one type of recombinant baculovirus which contains a gene encoding an interacting protein and a gene encoding a membrane-bound receptor protein which interacts with said interacting protein to perform its function, and co-expressing said interacting protein and said membrane-bound receptor protein in a budded baculovirus released from said host.

Method for expressing a functional membrane-bound receptor protein using budded baculovirus

Method for efficiently expressing a protein in an active form by using baculovirus expression system wherein the protein is selected from a membrane-bound enzyme, a substrate of the membrane-bound enzyme, a membrane-bound enzyme activator, a membrane-bound transport protein, a channel protein, a membrane structural protein, a protein involved in adhesion, a protein involved in antigen presentation, or a protein involved in formation of high dimensional structure of a protein. There is provided a method for expressing such a protein by culturing a host infected with at least one type of recombinant baculovirus which contains a gene encoding the protein, wherein the protein is expressed in a budded baculovirus released from the host.

Method for expressing and purifying proteins using budded baculovirus

Growing community of inventors

Tokyo, Japan

Takao Hamakubo